Navigation Links
Neurocrine Biosciences Reports Second Quarter 2011 Results
Date:7/28/2011

sess once-daily NBI-98854 (12.5mg and 50mg) over a two week dosing period. The primary endpoint of the study will be the Abnormal Involuntary Movement Scale (AIMS).

The Company has also started three-month in-vivo toxicology studies to support longer dosing regimens. This data is also expected during the fourth quarter of 2011. Pending the results of this toxicology study and the second Phase II study, a larger, Phase IIb study is planned to be initiated in early 2012 to assess three-month dosing of NBI-98854.

Urocortin 2 UpdateThe Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is enrolling patients with Acute Decompensated Heart Failure in a Phase II study of urocortin 2, and has enrolled 45 patients as of mid-July, of a planned total patient population of 50.

Additionally, urocortin 2 studies are underway at the Centre for Cardiovascular Sciences at The University of Edinburgh through a British Heart Foundation grant. Nine studies are expected to be conducted in both healthy volunteers and patients with stable congestive heart failure to determine the impact of urocortin 2 infusions on biomarkers of cardiovascular function and dysfunction.

The Company has completed several Phase I studies and two Phase II studies of urocortin 2 in patients with stable congestive heart failure. These Phase II studies showed urocortin 2 to be well tolerated with positive hemodynamic effects as evidenced by increases in cardiac output and efficiency.

Conference Call and Webcast Tomorrow at 8:00AM Eastern TimeNeurocrine will hold a live conference call and webcast tomorrow at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). Participants can access the live conference call by dialing 800-862-9098 (US) or 785-424-1051 (International) using the conference ID: 7NBIX. The call can also be accessed via the webcast through the Comp
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
2. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
3. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
6. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
7. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
8. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Huge event with 36,000+ global professionals is ... analysis and forecasting   CPhI Worldwide , ... most successful show to date with pre-audit figures estimating ... year in Paris , the show ... countries representing every step of the pharmaceutical supply chain ...
(Date:10/31/2014)... Ill. (PRWEB) October 31, 2014 Jeffrey ... Department of Historical Studies within the College of Arts ... SIUE to record the history of alcohol-based fuels in ... and many others have been working to build Illinois’ ... important but overlooked aspect of the state's agricultural and ...
(Date:10/31/2014)... 31, 2014 ENVIRON , ... announced today that Dr. Harvey Clewell III has ... will work closely with senior professionals in ENVIRON’s ... to serve at The Hamner Institutes for Health ... Carolina, where he is Director, Center for Human ...
(Date:10/30/2014)... LONDON , October 30, 2014 ... Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... PCYC ), Synthetic Biologics Inc. (NYSE MKT: SYN), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,549.23, down 0.33%, the Dow Jones ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... ... Capital,s client Neuren Pharmaceuticals Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible note private ... as Neuren,s exclusive placement agent and advisor. , ... New York (PRWEB) November 23, 2009 -- The independent ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced that it has ... common stock will be,suspended as of November 30, 2009 and a ... will remove deCODE,s common stock,from listing on Nasdaq, unless the company ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced the approval of all of ... Delaware,(the "Bankruptcy Court"). deCODE last week filed a voluntary petition for,relief under ... The orders issued by the Bankruptcy Court allow ...
Cached Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
(Date:10/29/2014)... and gas production are well over recommended levels in ... journal Environmental Health . High levels of benzene, ... the first to be based on community sampling by ... used to supplement official air-quality monitoring programs. , Unconventional ... readily flow to the surface. This is because they ...
(Date:10/29/2014)... been blamed for increasing the risk of a ... history of schizophrenia, are widely accepted. Others, such ... parasite transmitted by soil, undercooked meat and cat ... new study by Gary Smith, professor of population ... School of Veterinary Medicine, used epidemiological modeling methods ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... developed a small-molecule inhibitor of a protein that plays ... they show that the inhibitor can halt the growth ... culture. The findings are reported in companion papers reported ... Jan-Michael Peters of the Research Institute of Molecular Pathology ...
... developed at the University of Toronto is revealing biochemical ... could one day pave the way for pharmaceutical applications. ... issue of Molecular Cell describes how U of T ... test for proteins that play an important role in ...
... popular game fish mistaken by scientists for a dog ... reefs of the Abrolhos region of the South Atlantic ... discovery of Lutjanus alexandrei, a new snapper species that ... of Conservation International (CI) and Kenyon Lindeman of Environmental ...
Cached Biology News:New protein inhibitor impedes growth of cancerous cells 2Technology reveals 'lock and key' proteins behind diseases 2New species of snapper discovered in Brazil 2
... mg/L sodium pyruvate, 50 mg/L streptomycin sulfate, ... calcium chloride, and magnesium chloride. The use ... tissue culture is generally attributed to early ... Ringer developed a solution of inorganic salts ...
... dramatic breakthrough in accurate, small-volume bulk dispensing. Dispensing ... micro 1 has unique advantages not found in ... never needs re-calibration as do other 1mL dispensers. ... LCD Display , Graphical Row Selection , 96-,384- ...
... Rabbit polyclonal to Rad51 ( Abpromise ... Antigen: Synthetic peptide: ... N terminal amino acids 15-29 of ... Gene ID: 5888 ...
... performance agitation and temperature control for microbiology ... wells independently and is suitable for DASGIP ... working volume. Its temperature ranges from approximately ... well is equipped with an individual electrical ...
Biology Products: